文献速递复苏、休克与脓毒症儿科与产科急症重症综合管理与镇静镇痛

去甲肾上腺素联合多巴酚丁胺与肾上腺素作为儿童液体难治性冷休克一线血管活性药物的随机对照试验

A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock.
PubMed 文献 · Crit Care Explor · 2022-12-28
一句话结论在液体难治性冷休克患儿中,去甲肾上腺素联合多巴酚丁胺组休克缓解时间早于肾上腺素组(HR 1.84),但1小时缓解率差异无定论。

该单中心开放标签随机对照试验纳入67例2个月至18岁以下液体难治性冷休克患儿,比较去甲肾上腺素联合多巴酚丁胺(34例)与肾上腺素(33例)作为一线血管活性药物的效果。主要终点1小时休克缓解率两组分别为17.6%与9%(RR 2.0,95%CI 0.54-7.35,P=0.25),差异无统计学意义。去甲肾上腺素联合多巴酚丁胺组休克缓解时间更早(HR 1.84,95%CI 1.1-3.08),28天死亡率两组分别为23.5%与39.3%(RR 0.59,95%CI 0.28-1.25),差异无统计学意义。作者认为需进一步开展有足够把握度检测或排除重要差异的研究。

要点

  • 在液体难治性冷休克患儿中,去甲肾上腺素联合多巴酚丁胺组休克缓解时间早于肾上腺素组(HR 1.84,95%CI 1.1-3.08)。
  • 1小时休克缓解率去甲肾上腺素联合多巴酚丁胺组17.6% vs 肾上腺素组9%(RR 2.0,95%CI 0.54-7.35,P=0.25),差异无统计学意义。
  • 6小时休克缓解率去甲肾上腺素联合多巴酚丁胺组76.4% vs 肾上腺素组54.5%(RR 1.69,95%CI 0.92-3.13,P=0.06),差异无统计学意义。
  • 28天死亡率去甲肾上腺素联合多巴酚丁胺组23.5% vs 肾上腺素组39.3%(RR 0.59,95%CI 0.28-1.25),差异无统计学意义。
  • 作者结论认为1小时休克缓解率差异无定论,需进一步开展有足够把握度的研究来检测或排除重要差异。

适用人群与场景

  • 2个月至小于18岁儿童,液体难治性冷休克,来自印度北部单中心PICU。

处置流程与药物剂量

  • 干预组:去甲肾上腺素和多巴酚丁胺作为一线血管活性药物启动。
  • 对照组:肾上腺素作为一线血管活性药物启动。

研究设计与关键结果

  • 开放标签随机对照试验,单中心PICU,纳入67例患儿:去甲肾上腺素联合多巴酚丁胺组34例,肾上腺素组33例。
  • 主要终点1小时休克缓解率:去甲肾上腺素联合多巴酚丁胺组17.6% vs 肾上腺素组9%(RR 2.0,95%CI 0.54-7.35,P=0.25)。
  • 6小时休克缓解率:去甲肾上腺素联合多巴酚丁胺组76.4% vs 肾上腺素组54.5%(RR 1.69,95%CI 0.92-3.13,P=0.06)。
  • 24小时休克缓解率两组间无差异。
  • 休克缓解时间(从启动血管活性药物至达到全部治疗终点):去甲肾上腺素联合多巴酚丁胺组更早(HR 1.84,95%CI 1.1-3.08)。
  • 28天死亡率:去甲肾上腺素联合多巴酚丁胺组23.5% vs 肾上腺素组39.3%(RR 0.59,95%CI 0.28-1.25),差异无统计学意义。
  • 去甲肾上腺素联合多巴酚丁胺组对治疗难治的患儿更少。

证据类型、等级与局限

  • 证据类型:开放标签随机对照试验。
  • 局限:单中心;样本量小(67例);1小时休克缓解率差异无定论;作者指出需进一步开展有足够把握度检测或排除重要差异的研究。

对床旁实践的改变

  • 在液体难治性冷休克患儿中,使用去甲肾上腺素联合多巴酚丁胺作为一线血管活性药物可能使休克缓解时间更早(HR 1.84,95%CI 1.1-3.08),但1小时休克缓解率差异无定论,作者认为需进一步研究验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock.

DESIGN: Open-label randomized controlled study.

SETTING: A single-center PICU from North India.

PATIENTS: Children 2 months to less than 18 years old with fluid refractory cold septic shock.

INTERVENTIONS: In the intervention group, norepinephrine and dobutamine were started and in the control group, epinephrine was started as the first-line vasoactive agent. The primary outcome was the proportion attaining shock resolution (attaining all the therapeutic endpoints) at 1 hour of therapy.

MEASUREMENTS AND MAIN RESULTS: We enrolled 67 children: 34 in the norepinephrine plus dobutamine group (intervention) and 33 in the epinephrine group (control). There was no difference in shock resolution at 1 hour (17.6% vs 9%; risk ratio [RR], 2.0; 95% CI, 0.54-7.35; p = 0.25), 6 hours (76.4% vs 54.5%; RR, 1.69; 95% CI, 0.92-3.13; p = 0.06), and 24 hours between the intervention and control groups, respectively. Children in the norepinephrine plus dobutamine group attained shock resolution earlier (measured from starting of vasoactive agents to attaining all the therapeutic endpoints) (hazard ratio, 1.84 [1.1-3.08]). The difference in 28-day mortality was not significant (23.5% vs 39.3% in the intervention and control groups, respectively [RR, 0.59; 95% CI, 0.28-1.25]).

CONCLUSIONS: In children with fluid refractory cold septic shock, with use of norepinephrine plus dobutamine as first-line agents, the difference in the proportion of children attaining shock resolution at 1 hour between the groups was inconclusive. However, the time to shock resolution was earlier in the norepinephrine plus dobutamine group. Also, fewer children in the intervention group were refractory to treatment. Further studies powered to detect (or exclude) an important difference would be required to test this intervention.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Banothu KK, Sankar J, Kumar UV, et al. A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock. Crit Care Explor. 2022. PMID: 36600781. doi:10.1097/CCE.0000000000000815

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。